메뉴 건너뛰기




Volumn 5, Issue 2, 2010, Pages 99-108

The challenges of RSV vaccines. where do we stand?

Author keywords

Adjuvants; Dna vaccines; Live attenuated vaccines; RSV; RSV vaccine; Subunit vaccines

Indexed keywords

BBG2NA VIRUS VACCINE; BETA INTERFERON; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; DNA F VACCINE; DNA VACCINE; GAMMA INTERFERON; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 2; ISCOM; LIVE VACCINE; MEDI 534; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 2; OLIGONUCLEOTIDE; OUTER MEMBRANE PROTEIN; PHOSPHORYL LIPID A; PLASMID DNA; POLYSORBATE 20; PURIFIED F PROTEIN 1 VACCINE; PURIFIED F PROTEIN 2 VACCINE; QS 21; RECOMBINANT INTERLEUKIN 12; RESPIRATORY SYNCYTIAL VIRUS VACCINE; SAPONIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

EID: 77954050345     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489110791233504     Document Type: Article
Times cited : (10)

References (121)
  • 2
    • 0028946637 scopus 로고
    • Current approaches to the development of vaccinesagainst disease caused by respiratory syncytial virus (RSV) andparainfluenza virus (PIV). A meeting report of the WHOProgramme for Vaccine Development
    • Crowe JE Jr. Current approaches to the development of vaccinesagainst disease caused by respiratory syncytial virus (RSV) andparainfluenza virus (PIV). A meeting report of the WHOProgramme for Vaccine Development. Vaccine 1995; 13: 415-21.
    • (1995) Vaccine , vol.13 , pp. 415-421
    • Crowe Jr, J.E.1
  • 3
    • 77951101124 scopus 로고    scopus 로고
    • Review of palivizumab in the prophylaxis ofrespiratory synchytial virus (RSV) in high risk infants
    • Mejias A, Ramilo O. Review of palivizumab in the prophylaxis ofrespiratory synchytial virus (RSV) in high risk infants. Biologics 2008; 2: 433-9.
    • (2008) Biologics , vol.2 , pp. 433-439
    • Mejias, A.1    Ramilo, O.2
  • 4
    • 0347320936 scopus 로고    scopus 로고
    • Revised indications for theuse of palivizumab and respiratory syncytial virus immune globulinintravenous for the prevention of respiratory syncytial virusinfections
    • American Academy of Pediatrics Committee on Infectious Diseasesand Committee on Fetus and Newborn
    • American Academy of Pediatrics Committee on Infectious Diseasesand Committee on Fetus and Newborn. Revised indications for theuse of palivizumab and respiratory syncytial virus immune globulinintravenous for the prevention of respiratory syncytial virusinfections. Pediatrics 2003; 112: 1442-6.
    • (2003) Pediatrics , vol.112 , pp. 1442-1446
  • 8
    • 0025391838 scopus 로고
    • From the National Institute of Allergy and InfectiousDiseases and the World Health Organization. Respiratory syncytialand parainfluenza viruses
    • Heilman CA
    • Heilman CA. From the National Institute of Allergy and InfectiousDiseases and the World Health Organization. Respiratory syncytialand parainfluenza viruses. J Infect Dis 1990; 161: 402-6.
    • (1990) J Infect Dis , vol.161 , pp. 402-406
  • 9
    • 0022589125 scopus 로고
    • Risk of primaryinfection and reinfection with respiratory syncytial virus
    • Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primaryinfection and reinfection with respiratory syncytial virus. Am J DisChild 1986; 140: 543-6.
    • (1986) Am J DisChild , vol.140 , pp. 543-546
    • Glezen, W.P.1    Taber, L.H.2    Frank, A.L.3    Kasel, J.A.4
  • 11
    • 0035168864 scopus 로고    scopus 로고
    • Bronchiolitis - associated mortality and estimates of respiratorysyncytial virus associated-deaths among US children. 1979-1997
    • Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ.Bronchiolitis - associated mortality and estimates of respiratorysyncytial virus associated-deaths among US children. 1979-1997. JInfect Dis 2001; 183: 16-22.
    • (2001) JInfect Dis , vol.183 , pp. 16-22
    • Shay, D.K.1    Holman, R.C.2    Roosevelt, G.E.3    Clarke, M.J.4    Anderson, L.J.5
  • 12
    • 0031748527 scopus 로고
    • Respiratorysyncytial virus infection in tropical and developing countries
    • Weher MW, Mulholland EK, Greenwood BM. Respiratorysyncytial virus infection in tropical and developing countries. TropMed Int Health 1988; 3: 268-80.
    • (1988) TropMed Int Health , vol.3 , pp. 268-280
    • Weher, M.W.1    Mulholland, E.K.2    Greenwood, B.M.3
  • 13
    • 0033554244 scopus 로고    scopus 로고
    • Respiratory syncytial virus in early life and risk ofwheeze and allergy by age 13 years
    • Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, TaussigLM, et al. Respiratory syncytial virus in early life and risk ofwheeze and allergy by age 13 years. Lancet 1999; 354: 541-5.
    • (1999) Lancet , vol.354 , pp. 541-545
    • Stein, R.T.1    Sherrill, D.2    Morgan, W.J.3    Holberg, C.J.4    Halonen, M.5    Taussig, L.M.6
  • 14
    • 0033836306 scopus 로고    scopus 로고
    • The role of viral infections in the naturalhistory of asthma
    • Germ JE, Busse WW. The role of viral infections in the naturalhistory of asthma. J Allergy Clin Immunol 2000; 106: 201-12.
    • (2000) J Allergy Clin Immunol , vol.106 , pp. 201-212
    • Germ, J.E.1    Busse, W.W.2
  • 16
    • 0029737098 scopus 로고    scopus 로고
    • Respiratory syncytial virus is an important cause ofcommunity-acquired lower respiratory infection among hospitalizedadults
    • Dowell SF, Anderson LJ, Gary HE Jr, Erdman DD, Plouffe JF, FileTM Jr, et al. Respiratory syncytial virus is an important cause ofcommunity-acquired lower respiratory infection among hospitalizedadults. J Infect Dis 1996; 174: 456-62.
    • (1996) J Infect Dis , vol.174 , pp. 456-462
    • Dowell, S.F.1    Anderson, L.J.2    Gary Jr., H.E.3    Erdman, D.D.4    Plouffe, J.F.5    Film Jr, T.M.6
  • 17
    • 0033949819 scopus 로고    scopus 로고
    • Respiratory syncytial virus infection amonghospitalized adults
    • Falsey AR, Walsh EE. Respiratory syncytial virus infection amonghospitalized adults. Clin Microbiol Rev 2000; 13: 371-84.
    • (2000) Clin Microbiol Rev , vol.13 , pp. 371-384
    • Falsey, A.R.1    Walsh, E.E.2
  • 19
    • 35348828518 scopus 로고    scopus 로고
    • Understanding respiratorysyncytial virus (RSV) vaccine-enhanced disease
    • Castilow EM, Olson MR, Varga SM. Understanding respiratorysyncytial virus (RSV) vaccine-enhanced disease. Immunol Res2007; 39: 225-39.
    • (2007) Immunol Res , vol.39 , pp. 225-239
    • Castilow, E.M.1    Olson, M.R.2    Varga, S.M.3
  • 20
    • 33846270721 scopus 로고    scopus 로고
    • Prospects for developingvaccines without this complication
    • Little-van der Hurk SD, Mapletoft JW, Arsic N, Nolan JK.Immunopathology of RSV infection
    • Little-van der Hurk SD, Mapletoft JW, Arsic N, Nolan JK.Immunopathology of RSV infection: Prospects for developingvaccines without this complication. Rev Med Virol 2007; 17: 5-34.
    • (2007) Rev Med Virol , vol.17 , pp. 5-34
  • 21
    • 0023275087 scopus 로고
    • Demonstration thatglycoprotein G. is the attachment protein of respiratory syncytialvirus
    • Levine S, Klaiber-Franco R, Paradiso PR. Demonstration thatglycoprotein G is the attachment protein of respiratory syncytialvirus. J Gen Virol 1987; 68 (Pt 9): 2521-4.
    • (1987) J Gen Virol , vol.68 , Issue.Pt 9 , pp. 2521-2524
    • Levine, S.1    Klaiber-Franco, R.2    Paradiso, P.R.3
  • 22
    • 0023427601 scopus 로고
    • Antigenic relatedness between glycoproteins ofhuman respiratory syncytial virus subgroups A and B. Evaluation ofthe contributions of F and G glycoproteins to immunity
    • Johnson PR Jr, Olmsted RA, Prince GA, Murphy BR, Alling DW,Walsh EE, et al. Antigenic relatedness between glycoproteins ofhuman respiratory syncytial virus subgroups A and B. Evaluation ofthe contributions of F and G glycoproteins to immunity. J Virol1987; 61: 3163-6.
    • (1987) J Virol , vol.61 , pp. 3163-3166
    • Johnson Jr, P.R.1    Olmsted, R.A.2    Prince, G.A.3    Murphy, B.R.4
  • 23
    • 0036838764 scopus 로고    scopus 로고
    • Respiratory syncytial virus induced activationof nuclear factor -B in the lung involves alveolar macrophages andToll-like receptor 4-dependent pathways
    • Haeberle HA, Takizawa R, Casola A, Brasier AR, Dieterich HJ,Van Rooijen N, et al. Respiratory syncytial virus induced activationof nuclear factor -B in the lung involves alveolar macrophages andToll-like receptor 4-dependent pathways. J Infect Dis 2002;186:1199-206.
    • (2002) J Infect Dis , vol.186 , pp. 1199-1206
    • Haeberle, H.A.1    Takizawa, R.2    Casola, A.3    Brasier, A.R.4    Dieterich, H.J.5    van Rooijen, N.6
  • 24
    • 53849132415 scopus 로고    scopus 로고
    • Pulmonary immunity and immuno-pathology: Lessons from respiratory syncytial virus
    • Olson MR, Varga SM. Pulmonary immunity and immuno-pathology: lessons from respiratory syncytial virus. Expert RevVaccines 2008; 7: 1239-55.
    • (2008) Expert RevVaccines , vol.7 , pp. 1239-1255
    • Olson, M.R.1    Varga, S.M.2
  • 25
    • 34547124330 scopus 로고    scopus 로고
    • Function of therespiratory synchytial vrus small hydrophobic protein
    • Fuentes S, Tran KC, Luthra P, Teng MN, He B. Function of therespiratory synchytial vrus small hydrophobic protein. J Virol 2007;81: 8361-6.
    • (2007) J Virol , vol.81 , pp. 8361-8366
    • Fuentes, S.1    Tran, K.C.2    Luthra, P.3    Teng, M.N.4    He, B.5
  • 26
    • 0036229487 scopus 로고    scopus 로고
    • Respiratory syncytial virus (RSV)nonstructural (NS) proteins as host range determinants: A chimericbovine RSV with NS genes from human RSV is attenuated ininterferon-competent bovine cells
    • Bossert B, Conzelmann KK. Respiratory syncytial virus (RSV)nonstructural (NS) proteins as host range determinants: A chimericbovine RSV with NS genes from human RSV is attenuated ininterferon-competent bovine cells. J Virol 2002; 76: 4287-93.
    • (2002) J Virol , vol.76 , pp. 4287-4293
    • Bossert, B.1    Conzelmann, K.K.2
  • 27
    • 1842483896 scopus 로고    scopus 로고
    • Suppression ofthe induction of alpha, beta, and lambda interferons by the NS1 andNS2 proteins of human respiratory syncytial virus in humanepithelial cells and macrophages
    • Erratum2005, 6705-9
    • Spann KM, Tran KC, Chi B, Rabin RL, Collins PL. Suppression ofthe induction of alpha, beta, and lambda interferons by the NS1 andNS2 proteins of human respiratory syncytial virus in humanepithelial cells and macrophages. J Virol 2004; 78: 4363-9 (Erratum2005; 78: 6705-9).
    • (2004) J Virol , vol.78 , pp. 4363-4369
    • Spann, K.M.1    Tran, K.C.2    Chi, B.3    Rabin, R.L.4    Collins, P.L.5
  • 28
    • 33846815515 scopus 로고    scopus 로고
    • Nonstructural proteins of respiratory syncytialvirus suppress premature apoptosis by an NF- B-dependent,interferon-independent mechanism and facilitate virus growth
    • Bitko V, Shulyayeva O, Mazumder B, Musiyenko A, RamaswamyM, Look DC, et al. Nonstructural proteins of respiratory syncytialvirus suppress premature apoptosis by an NF- B-dependent,interferon-independent mechanism and facilitate virus growth. JVirol 2007; 81: 1786-95.
    • (2007) JVirol , vol.81 , pp. 1786-1795
    • Bitko, V.1    Shulyayeva, O.2    Mazumder, B.3    Musiyenko, A.4    Ramaswamy, M.5    Look, D.C.6
  • 29
    • 0014495164 scopus 로고
    • Firstevaluation of a respiratory syncytial virus vaccine and a trivalentparainfluenza virus vaccine in a pediatric population
    • Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Firstevaluation of a respiratory syncytial virus vaccine and a trivalentparainfluenza virus vaccine in a pediatric population. Am JEpidemiol 1969; 89: 449-63.
    • (1969) Am JEpidemiol , vol.89 , pp. 449-463
    • Chin, J.1    Magoffin, R.L.2    Shearer, L.A.3    Schieble, J.H.4    Lennette, E.H.5
  • 30
    • 0014495251 scopus 로고
    • Respiratory syncytial virus disease in infants despite prioradministration of antigenic inactivated vaccine
    • Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, JensenK, et al. Respiratory syncytial virus disease in infants despite prioradministration of antigenic inactivated vaccine. Am J Epidemiol1969; 89: 422-34.
    • (1969) Am J Epidemiol , vol.89 , pp. 422-434
    • Kim, H.W.1    Canchola, J.G.2    Brandt, C.D.3    Pyles, G.4    Chanock, R.M.5
  • 31
    • 0014493282 scopus 로고
    • An epidemiological study of altered clinical reactivity torespiratory syncytial (RS) virus infection in children previouslyvaccinated with an inactivated RS virus vaccine
    • Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiological study of altered clinical reactivity torespiratory syncytial (RS) virus infection in children previouslyvaccinated with an inactivated RS virus vaccine. Am J Epidemiol1969; 89: 405-21.
    • (1969) Am J Epidemiol , vol.89 , pp. 405-421
    • Kapikian, A.Z.1    Mitchell, R.H.2    Chanock, R.M.3    Shvedoff, R.A.4    Stewart, C.E.5
  • 32
    • 22244473286 scopus 로고    scopus 로고
    • Immune responses and diseaseenhancement during respiratory syncytial virus infection
    • Openshaw PJM, Tregoning JS. Immune responses and diseaseenhancement during respiratory syncytial virus infection. ClinMicrobiol Rev 2005; 18: 541-55.
    • (2005) ClinMicrobiol Rev , vol.18 , pp. 541-555
    • Openshaw, P.J.M.1    Tregoning, J.S.2
  • 33
    • 0022555443 scopus 로고
    • Dissociation between serum neutralizing andglycoprotein antibody responses of infants and children whoreceived inactivated respiratory sycytial virus vaccine
    • Murphy BR, Prince GA, Walsh EE, Kim HW, Parrott RH,Hemming VG, et al. Dissociation between serum neutralizing andglycoprotein antibody responses of infants and children whoreceived inactivated respiratory sycytial virus vaccine. J ClinMicrobiol 1986; 24: 197-202.
    • (1986) J ClinMicrobiol , vol.24 , pp. 197-202
    • Murphy, B.R.1    Prince, G.A.2    Walsh, E.E.3    Kim, H.W.4    Parrott, R.H.5    Hemming, V.G.6
  • 34
    • 40149098584 scopus 로고    scopus 로고
    • Human and bovine respiratorysyncytial virus vaccine research and development
    • Meyer G, Deplance M, Schelcher F. Human and bovine respiratorysyncytial virus vaccine research and development. Comp ImmunolMicrobiol Infect Dis 2008; 31: 191-225.
    • (2008) Comp ImmunolMicrobiol Infect Dis , vol.31 , pp. 191-225
    • Meyer, G.1    Deplance, M.2    Schelcher, F.3
  • 35
    • 33749256261 scopus 로고    scopus 로고
    • Respiratory syncytial virus diseasemechanisms implicated by human, animal model, and in vitro datafacilitate vaccine strategies and new therapeutics
    • Moore ML, Peebles RS Jr. Respiratory syncytial virus diseasemechanisms implicated by human, animal model, and in vitro datafacilitate vaccine strategies and new therapeutics. Pharmacol Ther2006; 112: 405-24.
    • (2006) Pharmacol Ther , vol.112 , pp. 405-424
    • Moore, M.L.1    Peebles Jr., R.S.2
  • 36
    • 0347479195 scopus 로고    scopus 로고
    • Progress in the development of respiratorysyncytial virus and parainfluenza virus vaccines
    • Durbin AP, Karron RA. Progress in the development of respiratorysyncytial virus and parainfluenza virus vaccines. Clin Infect Dis2003; 37: 1668-77.
    • (2003) Clin Infect Dis , vol.37 , pp. 1668-1677
    • Durbin, A.P.1    Karron, R.A.2
  • 37
    • 1842684459 scopus 로고    scopus 로고
    • IL-4utilizes an alternative receptor to drive apoptosis of Th1 cells andskews neonatal immunity toward Th2
    • Li L, Lee HH, Bell JJ, Gregg RK, Ellis JS, Gessner A, et al. IL-4utilizes an alternative receptor to drive apoptosis of Th1 cells andskews neonatal immunity toward Th2. Immunity 2004; 20: 429-40.
    • (2004) Immunity , vol.20 , pp. 429-440
    • Li, L.1    Lee, H.H.2    Bell, J.J.3    Gregg, R.K.4    Ellis, J.S.5    Gessner, A.6
  • 38
    • 0035815511 scopus 로고    scopus 로고
    • Pathogenesis ofRSV Lower respiratory tract infection: Implications for vaccinedevelopment
    • Brandenburg AH, Neijens HJ, Osterhaus ADME. Pathogenesis ofRSV Lower respiratory tract infection: implications for vaccinedevelopment. Vaccine 2001; 19: 2769-82.
    • (2001) Vaccine , vol.19 , pp. 2769-2782
    • Brandenburg, A.H.1    Neijens, H.J.2    Osterhaus, A.D.M.E.3
  • 39
    • 0020572023 scopus 로고
    • Antibodies torespiratory syncytial virus polypeptides and their significance inhuman infection
    • Ward KA, Lambden PR, Ogilvie MM, Watt PJ. Antibodies torespiratory syncytial virus polypeptides and their significance inhuman infection. J Gen Virol 1983; 64: 1867-76.
    • (1983) J Gen Virol , vol.64 , pp. 1867-1876
    • Ward, K.A.1    Lambden, P.R.2    Ogilvie, M.M.3    Watt, P.J.4
  • 40
    • 0027384670 scopus 로고
    • Prophylactic administration of respiratory syncytial virusimmune globulin to high risk infants and young children. Therespiratory synchytial virus immune globulin study group
    • Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, RodriguezWJ, et al. Prophylactic administration of respiratory syncytial virusimmune globulin to high risk infants and young children. Therespiratory synchytial virus immune globulin study group. N Engl JMed 1993; 329: 1524-30.
    • (1993) N Engl JMed , vol.329 , pp. 1524-1530
    • Groothuis, J.R.1    Simoes, E.A.2    Levin, M.J.3    Hall, C.B.4    Long, C.E.5    Rodriguez, W.J.6
  • 41
    • 1342329509 scopus 로고    scopus 로고
    • Respiratory syncytial virus: The virus, the disease and theimmune response
    • Olgra PL. Respiratory syncytial virus: The virus, the disease and theimmune response. Paediatr Respir Rev 2004; 5(Suppl A): S119-S126.
    • (2004) Paediatr Respir Rev , vol.5 , Issue.SUPPL. A
    • Olgra, P.L.1
  • 42
    • 38449084342 scopus 로고    scopus 로고
    • Cd8 T Cells inhibit respiratory syncytialvirus (RSV) vaccine-enhanced disease
    • Olson MR, Varga SM. CD8 T cells inhibit respiratory syncytialvirus (RSV) vaccine-enhanced disease. J Immunol 2007; 179:5415-24.
    • (2007) J Immunol , vol.179 , pp. 5415-5424
    • Olson, M.R.1    Varga, S.M.2
  • 43
    • 71849118589 scopus 로고    scopus 로고
    • The number of RSV-specificmemory CD8 T cells in the lung is critical for their ability to inhibitrespiratory syncytial virus (RSV) vaccine-enhanced pulmonaryeosinophilia
    • Olson MR, Hartwig SM, Varga SM. The number of RSV-specificmemory CD8 T cells in the lung is critical for their ability to inhibitrespiratory syncytial virus (RSV) vaccine-enhanced pulmonaryeosinophilia. J Immunol 2008; 181: 7958-68.
    • (2008) J Immunol , vol.181 , pp. 7958-7968
    • Olson, M.R.1    Hartwig, S.M.2    Varga, S.M.3
  • 44
    • 0028107250 scopus 로고
    • Distinct types of lungdisease caused by functional subsets of antiviral T cells
    • Alwan WH, Kozlowska WJ, Openshaw PJ. Distinct types of lungdisease caused by functional subsets of antiviral T cells. J Exp Med1994; 179: 81-9.
    • (1994) J Exp Med , vol.179 , pp. 81-89
    • Alwan, W.H.1    Kozlowska, W.J.2    Openshaw, P.J.3
  • 45
    • 0026460748 scopus 로고
    • Pulmonary histopathology induced byrespiratory syncytial virus (RSV) challenge of formalin-inactivatedRSV-immunized BALB/c mice is abrogated by depletion of CD4+T cells
    • Connors M, Kulkarni AB, Firestone CY, Holmes KL, Morse HC3rd, Sotnikov AV, et al. Pulmonary histopathology induced byrespiratory syncytial virus (RSV) challenge of formalin-inactivatedRSV-immunized BALB/c mice is abrogated by depletion of CD4+T cells. J Virol 1992; 66: 7444-51.
    • (1992) J Virol , vol.66 , pp. 7444-7451
    • Connors, M.1    Kulkarni, A.B.2    Firestone, C.Y.3    Holmes, K.L.4    Morse 3rd, H.C.5    Sotnikov, A.V.6
  • 46
    • 0034749998 scopus 로고    scopus 로고
    • Infection is mediated by a discrete oligoclonal subset ofantigen-specific CD4 (+) T cells
    • Varga SM, Wang X, WElsch RM, Braciale TJ. Immunopathologyin RSV infection is mediated by a discrete oligoclonal subset ofantigen-specific CD4 (+) T cells. Immunity 2001; 15: 637-46.
    • (2001) Immunity , vol.15 , pp. 637-646
    • Varga, S.M.1    Wang, X.2    Welsch, R.M.3    Braciale, T.J.4    Immunopathologyin, R.S.V.5
  • 47
    • 45749110581 scopus 로고    scopus 로고
    • RSV 2007: Recent advancesin respiratory syncytial virus research
    • Stevens WW, Falsey AR, Braciale TJ. RSV 2007: Recent advancesin respiratory syncytial virus research. Viral Immunol 2008; 21:133-40.
    • (2008) Viral Immunol , vol.21 , pp. 133-140
    • Stevens, W.W.1    Falsey, A.R.2    Braciale, T.J.3
  • 48
    • 55849152459 scopus 로고    scopus 로고
    • Overcoming T cell mediated immuno-pathology to achieve safe RSV vaccination
    • Castilow EM, Varga S. Overcoming T cell mediated immuno-pathology to achieve safe RSV vaccination. Future Virol 2008; 3:445-54.
    • (2008) Future Virol , vol.3 , pp. 445-454
    • Castilow, E.M.1    Varga, S.2
  • 49
    • 0028241420 scopus 로고
    • HildrethS. Respiratory syncytial virus specific cell mediated immuneresponses after vaccination with a purified fusion protein subunitvaccine
    • Welliver RC, Tristram DA, Batt K, Sun M, Hogerman D, HildrethS. Respiratory syncytial virus specific cell mediated immuneresponses after vaccination with a purified fusion protein subunitvaccine. J Infect Dis 1994; 170: 425-8.
    • (1994) J Infect Dis , vol.170 , pp. 425-428
    • Welliver, R.C.1    Tristram, D.A.2    Batt, K.3    Sun, M.4    Hogerman, D.5
  • 50
    • 0030250348 scopus 로고    scopus 로고
    • Safety and immunogenicity of a respiratorysyncytial virus subunit vaccine (PFP-2) in ambulatory adults overage 60
    • Falsey AR, Walsh EE. Safety and immunogenicity of a respiratorysyncytial virus subunit vaccine (PFP-2) in ambulatory adults overage 60. Vaccine 1996; 14:1214-8.
    • (1996) Vaccine , vol.14 , pp. 1214-1218
    • Falsey, A.R.1    Walsh, E.E.2
  • 51
    • 0030031491 scopus 로고    scopus 로고
    • Purified fusion protein vaccine protects against lowerrespiratory tract illness during respiratory syncytial virus season inchildren with cystic fibrosis
    • Piedra PE, Grace S, Jewell A, Spinelli S, Bunting D, HogermanDA, et al. Purified fusion protein vaccine protects against lowerrespiratory tract illness during respiratory syncytial virus season inchildren with cystic fibrosis. Pediatr Infect Dis J 1996; 15: 23-31.
    • (1996) Pediatr Infect Dis J , vol.15 , pp. 23-31
    • Piedra, P.E.1    Grace, S.2    Jewell, A.3    Spinelli, S.4    Bunting, D.5    Hogerman, D.A.6
  • 52
    • 0030793204 scopus 로고    scopus 로고
    • Safety and immunogenicity of a respiratorysyncytial virus subunit vaccine (PFP-2) in the institutionalizedelderly
    • Falsey AR, Walsh EE. Safety and immunogenicity of a respiratorysyncytial virus subunit vaccine (PFP-2) in the institutionalizedelderly. Vaccine 1997; 15: 1130-2.
    • (1997) Vaccine , vol.15 , pp. 1130-1132
    • Falsey, A.R.1    Walsh, E.E.2
  • 53
    • 0031906484 scopus 로고    scopus 로고
    • Safety and immunogenicity of a purified F protein respiratorysyncytial virus (PFP-2) vaccine in seropositive children withbronchopulmonary dysplasia
    • Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EA.Safety and immunogenicity of a purified F protein respiratorysyncytial virus (PFP-2) vaccine in seropositive children withbronchopulmonary dysplasia. J Infect Dis 1998; 177: 467-9.
    • (1998) J Infect Dis , vol.177 , pp. 467-469
    • Groothuis, J.R.1    King, S.J.2    Hogerman, D.A.3    Paradiso, P.R.4    Simoes, E.A.5
  • 54
    • 0027463527 scopus 로고
    • HImmunogenicity and safety of respiratory syncytialvirus subunit vaccine in seropositive children 18-36 months
    • Tristram DA, Welliver RC, Mohar CK, Hogerman DA, HildrethSW, Paradiso P. Immunogenicity and safety of respiratory syncytialvirus subunit vaccine in seropositive children 18-36 months. JInfect Dis 1993; 167:191-5.
    • (1993) JInfect Dis , vol.167 , pp. 191-195
    • Tristram, D.A.1    Welliver, R.C.2    Mohar, C.K.3    Hogerman, D.A.4    Hildreth, S.W.5    Paradiso, P.6
  • 55
    • 0028288689 scopus 로고
    • Second year surveillance of respiratory syncytial virus (RSV) Fprotein subunit vaccine, PFP-1: Evaluation of antibody persistenceand possible disease enhancement
    • Tristram DA, Welliver RC, Hogerman DA, Hildreth SW, ParadisoP. Second year surveillance of respiratory syncytial virus (RSV) Fprotein subunit vaccine, PFP-1: Evaluation of antibody persistenceand possible disease enhancement. Vaccine 1994; 12: 551-6.
    • (1994) Vaccine , vol.12 , pp. 551-556
    • Tristram, D.A.1    Welliver, R.C.2    Hogerman, D.A.3    Hildreth, S.W.4    Paradiso, P.5
  • 57
    • 0031894642 scopus 로고    scopus 로고
    • Sequential annual administration of purified fusion proteinvaccine against respiratory syncytial virus in children with cysticfibrosis
    • Piedra PA, Grace S, Jewell A, Spinelli S, Hogerman DA, MalinoskiF, et al. Sequential annual administration of purified fusion proteinvaccine against respiratory syncytial virus in children with cysticfibrosis. Pediatr Infect Dis J 1998; 17: 217-24.
    • (1998) Pediatr Infect Dis J , vol.17 , pp. 217-224
    • Piedra, P.A.1    Grace, S.2    Jewell, A.3    Spinelli, S.4    Hogerman, D.A.5    Malinoski, F.6
  • 58
    • 0038384095 scopus 로고    scopus 로고
    • Safety and immunogenicity ofrespiratory syncytial virus purified fusion protein-2 vaccine inpregnant women
    • Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity ofrespiratory syncytial virus purified fusion protein-2 vaccine inpregnant women. Vaccine 2003; 21: 3465-7.
    • (2003) Vaccine , vol.21 , pp. 3465-3467
    • Munoz, F.M.1    Piedra, P.A.2    Glezen, W.P.3
  • 59
    • 69749092449 scopus 로고    scopus 로고
    • A dose-ranging study of a subunit Respiratory SyncytialVirus subtype A vaccine with and without aluminium phosphateadjuvantation in adults > or =65 years of age
    • Langley JM, Sales V, McGeer A, Guasparini R, Predy G, MeekisonW, et al. A dose-ranging study of a subunit Respiratory SyncytialVirus subtype A vaccine with and without aluminium phosphateadjuvantation in adults > or =65 years of age. Vaccine 2009; 27:5913-9.
    • (2009) Vaccine , vol.27 , pp. 5913-5919
    • Langley, J.M.1    Sales, V.2    McGeer, A.3    Guasparini, R.4    Predy, G.5    Meekison, W.6
  • 60
    • 0035852331 scopus 로고    scopus 로고
    • Respiratorysyncytial virus vaccine: A systematic overview with emphasis onrespiratory syncytial virus subunit vaccines
    • Simoes EA, Tan DH, Ohlsson A, Sales V, Wang EE. Respiratorysyncytial virus vaccine: A systematic overview with emphasis onrespiratory syncytial virus subunit vaccines. Vaccine 2001; 20: 954-60.
    • (2001) Vaccine , vol.20 , pp. 954-960
    • Simoes, E.A.1    Tan, D.H.2    Ohlsson, A.3    Sales, V.4    Wang, E.E.5
  • 61
    • 0034080129 scopus 로고    scopus 로고
    • Serum neutralizing antibodytiters of seropositive chimpanzees immunized with vaccines co-formulated with natural fusion and attachment proteins ofrespiratory syncytial virus
    • Hancock GE, Smith JD, Heers KM. Serum neutralizing antibodytiters of seropositive chimpanzees immunized with vaccines co-formulated with natural fusion and attachment proteins ofrespiratory syncytial virus. J Infect Dis 2000; 181:1768-71.
    • (2000) J Infect Dis , vol.181 , pp. 1768-1771
    • Hancock, G.E.1    Smith, J.D.2    Heers, K.M.3
  • 62
    • 0026084919 scopus 로고
    • Vaccination of cotton rats with a chimeric FGglycoprotein of human respiratory syncytial virus induces minimalpulmonary pathology on challenge
    • Wathen MW, Kakuk TJ, Brideau RJ, Hausknecht EC, Cole SL,Zaya RM. Vaccination of cotton rats with a chimeric FGglycoprotein of human respiratory syncytial virus induces minimalpulmonary pathology on challenge. J Infect Dis 1991; 163: 477-82.
    • (1991) J Infect Dis , vol.163 , pp. 477-482
    • Wathen, M.W.1    Kakuk, T.J.2    Brideau, R.J.3    Hausknecht, E.C.4    Cole, S.L.5    Zaya, R.M.6
  • 63
    • 0026581303 scopus 로고
    • Cotton rats previously immunized with a chimericRSV FG glycoprotein develop enhanced pulmonary pathologywhen infected with RSV, a phenomenon not encountered followingimmunization with vaccinia-RSV recombinants or RSV
    • Connors M, Collins PL, Firestone CY, Sotnikov AV, Cotton rats previously immunized with a chimericRSV FG glycoprotein develop enhanced pulmonary pathologywhen infected with RSV, a phenomenon not encountered followingimmunization with vaccinia-RSV recombinants or RSV. Vaccine1992; 10: 475-84.
    • (1992) Vaccine , vol.10 , pp. 475-484
    • Connors, M.1    Collins, P.L.2    Firestone, C.Y.3    Sotnikov, A.V.4    Waitze, A.5    Davis, A.R.6
  • 64
    • 0031848862 scopus 로고    scopus 로고
    • Respiratory syncytial virus vaccines
    • Dudas R, Karron RA. Respiratory syncytial virus vaccines. ClinMicrobiol Rev 1998; 11: 430-9.
    • (1998) ClinMicrobiol Rev , vol.11 , pp. 430-439
    • Dudas, R.1    Karron, R.A.2
  • 65
    • 0030968130 scopus 로고    scopus 로고
    • Induction of protective immunity in rodents by vaccinationwith a prokaryotically expressed recombinant fusion proteincontaining a respiratory syncytial virus G protein fragment
    • Power UF, Plotnicky-Gilquin H, Huss T, Robert A, Trudel M, Ståhl S, et al. Induction of protective immunity in rodents by vaccinationwith a prokaryotically expressed recombinant fusion proteincontaining a respiratory syncytial virus G protein fragment.Virology 1997; 230: 155-66.
    • (1997) Virology , vol.230 , pp. 155-166
    • Power, U.F.1    Plotnicky-Gilquin, H.2    Huss, T.3    Robert, A.4    Trudel, M.5    Ståhl, S.6
  • 66
    • 0030820061 scopus 로고    scopus 로고
    • Protective immunity against respiratorysyncytial virus in early life after murine maternal or neonatalvaccination with the recombinant G fusion protein BBG2Na
    • Brandt C, Power UF, Plotnicky-Gilquin H, Huss T, Nguyen T,Lambert PH, et al. Protective immunity against respiratorysyncytial virus in early life after murine maternal or neonatalvaccination with the recombinant G fusion protein BBG2Na. JInfect Dis 1997; 176: 884-91.
    • (1997) JInfect Dis , vol.176 , pp. 884-891
    • Brandt, C.1    Power, U.F.2    Plotnicky-Gilquin, H.3    Huss, T.4    Nguyen, T.5    Lambert, P.H.6
  • 67
    • 0030744003 scopus 로고    scopus 로고
    • Challenge of BALB/c Mice With Respiratory Syncytial Virusdoes Not Enhance the Th2 Pathway Induced After Immunization Witha Recombinant G Fusion Protein, BBG2Na, In Aluminum Hydroxide
    • Corvaia N, Tournier P, Nguyen TN, Haeuw JF, Power UF, Binz H,et al. Challenge of BALB/c mice with respiratory syncytial virusdoes not enhance the Th2 pathway induced after immunization witha recombinant G Fusion protein, BBG2Na, in aluminum hydroxide.J Infect Dis 1997; 176: 560-9.
    • (1997) J Infect Dis , vol.176 , pp. 560-569
    • Corvaia, N.1    Tournier, P.2    Nguyen, T.N.3    Haeuw, J.F.4    Power, U.F.5    Binz, H.6
  • 68
    • 34447581209 scopus 로고    scopus 로고
    • Neonatal human autologousdentritic cells pulsed with recombinant protein antigen prime thegeneration of non polarized CD4 T-cell effectors
    • Matthews NC, Power UF, Reen DJ. Neonatal human autologousdentritic cells pulsed with recombinant protein antigen prime thegeneration of non polarized CD4 T-cell effectors. Int Immunol2007; 19: 703-12.
    • (2007) Int Immunol , vol.19 , pp. 703-712
    • Matthews, N.C.1    Power, U.F.2    Reen, D.J.3
  • 69
    • 0033602701 scopus 로고    scopus 로고
    • Absence of lung immunopathology followingrespiratory syncytial virus (RSV) challenge in mice immunizedwith a recombinant RSV G fragment
    • Plotnicky-Gilquin H, Huss T, Aubry JP, Haeuw JF, Beck A,Bonnefoy JY, et al. Absence of lung immunopathology followingrespiratory syncytial virus (RSV) challenge in mice immunizedwith a recombinant RSV G fragment. Virology 1999; 258: 128-40.
    • (1999) Virology , vol.258 , pp. 128-140
    • Plotnicky-Gilquin, H.1    Huss, T.2    Aubry, J.P.3    Haeuw, J.F.4    Beck, A.5    Bonnefoy, J.Y.6
  • 70
    • 0034212718 scopus 로고    scopus 로고
    • Influence of live respiratory syncytial viruspriming on the immune response generated by a recombinantvaccine candidate, BBG2Na
    • Goestch L, Plotnicky-Gilquin H, Champion T, Beck A, Haeuw JF,Nguyen T, et al. Influence of live respiratory syncytial viruspriming on the immune response generated by a recombinantvaccine candidate, BBG2Na. Vaccine 2000; 18: 2648-55.
    • (2000) Vaccine , vol.18 , pp. 2648-2655
    • Goestch, L.1    Plotnicky-Gilquin, H.2    Champion, T.3    Beck, A.4    Haeuw, J.F.5    Nguyen, T.6
  • 71
    • 0034212397 scopus 로고    scopus 로고
    • Influence of administration dose and route on theimmunogenicity and protective efficacy of BBG2Na, a recombinantrespiratory syncytial virus subunit vaccine candidate
    • Goetsch L, Plotnicky- Gilquin H, Champion T, Beck A, Corvaïa N,Stâhl S, et al. Influence of administration dose and route on theimmunogenicity and protective efficacy of BBG2Na, a recombinantrespiratory syncytial virus subunit vaccine candidate. Vaccine 2000;18: 2735-42.
    • (2000) Vaccine , vol.18 , pp. 2735-2742
    • Goetsch, L.1    Plotnicky-Gilquin, H.2    Champion, T.3    Beck, A.4    Corvaïa, N.5    Stâhl, S.6
  • 72
    • 0035577405 scopus 로고    scopus 로고
    • Safety and immunogenenicity of a novelrecombinant subunit respiratory syncytial virus vaccine (BBG2Na)in healthy young adults
    • Power UF, Nguyen TN, Rietveld E, de Swart RL, Groen J,Osterhaus AD, et al. Safety and immunogenenicity of a novelrecombinant subunit respiratory syncytial virus vaccine (BBG2Na)in healthy young adults. J Infect Dis 2001; 184: 1456-60.
    • (2001) J Infect Dis , vol.184 , pp. 1456-1460
    • Power, U.F.1    Nguyen, T.N.2    Rietveld, E.3    de Swart, R.L.4    Groen, J.5    Osterhaus, A.D.6
  • 73
    • 0036928450 scopus 로고    scopus 로고
    • Passive transfer of serum antibodiesinduced by BBG2Na, a subunit vaccine, in the elderly protectsSCID mouse lungs against respiratory syncytial virus challenge
    • Plotnicky-Gilquin H, Cyblat-Chanal D, Goetsch L, Lacheny C,Libon C, Champion T, et al. Passive transfer of serum antibodiesinduced by BBG2Na, a subunit vaccine, in the elderly protectsSCID mouse lungs against respiratory syncytial virus challenge.Virology 2002; 303: 130-7.
    • (2002) Virology , vol.303 , pp. 130-137
    • Plotnicky-Gilquin, H.1    Cyblat-Chanal, D.2    Goetsch, L.3    Lacheny, C.4    Libon, C.5    Champion, T.6
  • 74
    • 34748908970 scopus 로고    scopus 로고
    • Long lastingbalanced immunity and protective efficacy against respiratorysyncytial virus in mice induced by a recombinant protein G1F/M2
    • Zeng R, Qi X, Gong W, Mei X, Wei L, Ma C, et al. Long lastingbalanced immunity and protective efficacy against respiratorysyncytial virus in mice induced by a recombinant protein G1F/M2.Vaccine 2007; 25: 7422-8.
    • (2007) Vaccine , vol.25 , pp. 7422-7428
    • Zeng, R.1    Qi, X.2    Gong, W.3    Mei, X.4    Wei, L.5    Ma, C.6
  • 75
  • 77
    • 0032147238 scopus 로고    scopus 로고
    • Vaccinestrategies to overcome maternal antibody mediated inhibition ofmeasles vaccine
    • Osterhaus A, van Amerongen G, van Binnendijk R. Vaccinestrategies to overcome maternal antibody mediated inhibition ofmeasles vaccine. Vaccine 1998; 16: 1479-81.
    • (1998) Vaccine , vol.16 , pp. 1479-1481
    • Osterhaus, A.1    van Amerongen, G.2    van Binnendijk, R.3
  • 80
    • 0030657620 scopus 로고    scopus 로고
    • Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccinesin chimpanzees and in human adults, infants and children
    • Karron RA, Wright PF, Crowe JEJr. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccinesin chimpanzees and in human adults, infants and children. J InfectDis 1997; 176:1428-36.
    • (1997) J InfectDis , vol.176 , pp. 1428-1436
    • Karron, R.A.1    Wright, P.F.2    Crowe Jr, J.E.3
  • 81
    • 0033997580 scopus 로고    scopus 로고
    • Evaluation of the live attenuated cpts 248/404RSV vaccine in combination with a subunit RSV vaccine (PFP-2)in healthy young and older adults
    • Gonzalez IM, Karron RA, Eichelberger M, Walsh EE, DelagarzaVW, Bennett R, et al. Evaluation of the live attenuated cpts 248/404RSV vaccine in combination with a subunit RSV vaccine (PFP-2)in healthy young and older adults. Vaccine 2000; 18: 1763-72.
    • (2000) Vaccine , vol.18 , pp. 1763-1772
    • Gonzalez, I.M.1    Karron, R.A.2    Eichelberger, M.3    Walsh, E.E.4    Delagarza, V.W.5    Bennett, R.6
  • 82
    • 0033791293 scopus 로고    scopus 로고
    • Evaluation of a live, cold passaged, temperature -sensitive, respiratory syncytial virus vaccine candidate in infancy
    • Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE Jr,Boyce TG, et al. Evaluation of a live, cold passaged, temperature -sensitive, respiratory syncytial virus vaccine candidate in infancy. JInfect Dis 2000; 182: 1331-42.
    • (2000) JInfect Dis , vol.182 , pp. 1331-1342
    • Wright, P.F.1    Karron, R.A.2    Belshe, R.B.3    Thompson, J.4    Crowe Jr, J.E.5    Boyce, T.G.6
  • 83
    • 4644282211 scopus 로고    scopus 로고
    • Parainfluenza virus type 3 expressing in native or solublefusion (F) protein of respiratory syncytial virus (RSV) confersprotection from RSV infection in African green monkeys
    • Tang RS, MacPhail M, Schickli JH, Kaur J, Robinson CL, LawlorHA, et al. Parainfluenza virus type 3 expressing in native or solublefusion (F) protein of respiratory syncytial virus (RSV) confersprotection from RSV infection in African green monkeys. J Virol2004; 78: 11198-207.
    • (2004) J Virol , vol.78 , pp. 11198-207
    • Tang, R.S.1    Macphail, M.2    Schickli, J.H.3    Kaur, J.4    Robinson, C.L.5    Lawlor, H.A.6
  • 84
    • 55749098115 scopus 로고    scopus 로고
    • Development of a PIV-vectored RSV vaccine:Preclinical evaluation of safety, toxicity, and enhanced disease andinitial clinical testing in healthy adults
    • Tang RS, Spaete RR, Thompson MW, MacPhail M, Guzzetta JM,Ryan PC, et al. Development of a PIV-vectored RSV vaccine:Preclinical evaluation of safety, toxicity, and enhanced disease andinitial clinical testing in healthy adults. Vaccine 2008; 26: 6373-82.
    • (2008) Vaccine , vol.26 , pp. 6373-6382
    • Tang, R.S.1    Spaete, R.R.2    Thompson, M.W.3    Macphail, M.4    Guzzetta, J.M.5    Ryan, P.C.6
  • 85
    • 20144370691 scopus 로고    scopus 로고
    • Identification of a recombinant live attenuated respiratorysyncytial virus vaccine candidate that is highly attenuated in infants
    • Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, NewmanF, et al. Identification of a recombinant live attenuated respiratorysyncytial virus vaccine candidate that is highly attenuated in infants.J Infect Dis 2005; 191: 1093-104.
    • (2005) J Infect Dis , vol.191 , pp. 1093-1104
    • Karron, R.A.1    Wright, P.F.2    Belshe, R.B.3    Thumar, B.4    Casey, R.5    Newman, F.6
  • 86
    • 32044433987 scopus 로고    scopus 로고
    • The interferon antagonist NS2 protein of respiratory syncytialvirus is an important virulence determinant for humans
    • Wright PF, Karron RA, Madhi SA, Treanor JJ, King JC, O'Shea A,et al. The interferon antagonist NS2 protein of respiratory syncytialvirus is an important virulence determinant for humans. J Infect Dis2006; 15: 193: 573-81.
    • (2006) J Infect Dis , vol.15 , Issue.193 , pp. 573-581
    • Wright, P.F.1    Karron, R.A.2    Madhi, S.A.3    Treanor, J.J.4    King, J.C.5    O'Shea, A.6
  • 87
    • 0033997580 scopus 로고    scopus 로고
    • Evaluation of the live attenuated cpts248/404 RSV vaccine in combination with a subunit RSV vaccine(PFP-2) in healthy young and older adults
    • Gonzalez IM, Karron RA, Eichelberger M, Walsh EE, DelagarzaVW, Bennett R, et al. Evaluation of the live attenuated cpts248/404 RSV vaccine in combination with a subunit RSV vaccine(PFP-2) in healthy young and older adults. Vaccine 2000; 18: 1763-72.
    • (2000) Vaccine , vol.18 , pp. 1763-1772
    • Gonzalez, I.M.1    Karron, R.A.2    Eichelberger, M.3    Walsh, E.E.4    Delagarza, V.W.5    Bennett, R.6
  • 88
    • 0037484129 scopus 로고    scopus 로고
    • Mechanisms by which maternal antibodies influenceinfant vaccine responses: Review of hypotheses and definition ofmain determinants
    • Siegrist CA. Mechanisms by which maternal antibodies influenceinfant vaccine responses: review of hypotheses and definition ofmain determinants. Vaccine 2003; 21: 3406-12
    • (2003) Vaccine , vol.21 , pp. 3406-3412
    • Siegrist, C.A.1
  • 89
    • 0030711687 scopus 로고    scopus 로고
    • DNA immunization of neonatesinduces immunity despite the presence of maternal antibody
    • Manickan E, Yu Z, Rouse BT. DNA immunization of neonatesinduces immunity despite the presence of maternal antibody. J ClinInvest 1997; 100: 2371-5.
    • (1997) J ClinInvest , vol.100 , pp. 2371-2375
    • Manickan, E.1    Yu, Z.2    Rouse, B.T.3
  • 90
    • 18344410538 scopus 로고    scopus 로고
    • Protection against respiratory syncytial virus infection byDNA immunization
    • Li X, Sambhara S, Li CX, Ewasyshyn M, Parrington M, Caterini J,et al. Protection against respiratory syncytial virus infection byDNA immunization. J Exp Med 1998; 188: 681-8.
    • (1998) J Exp Med , vol.188 , pp. 681-688
    • Li, X.1    Sambhara, S.2    Li, C.X.3    Ewasyshyn, M.4    Parrington, M.5    Caterini, J.6
  • 91
    • 0034732137 scopus 로고    scopus 로고
    • Plasmid DNA encoding the respiratory sycytial virus G protein is apromising vaccine candidate
    • Li X, Sambhara S, Li CX, Switzer I, Cates G, James O, et al.Plasmid DNA encoding the respiratory sycytial virus G protein is apromising vaccine candidate. Virology 2000; 269: 54-65.
    • (2000) Virology , vol.269 , pp. 54-65
    • Li, X.1    Sambhara, S.2    Li, C.X.3    Switzer, I.4    Cates, G.5    James, O.6
  • 92
    • 0033804606 scopus 로고    scopus 로고
    • DNA encoding the attachment (G) or fusion (F) proteinor respiratory syncytial virus induces protection in the absence ofpulmonary inflammation
    • Bembridge GP, Rodriguez N, Beato GR, Nicolson C, Melero JA,Taylor G. DNA encoding the attachment (G) or fusion (F) proteinor respiratory syncytial virus induces protection in the absence ofpulmonary inflammation. J Gen Virol 2000; 81: 2519-23.
    • (2000) J Gen Virol , vol.81 , pp. 2519-2523
    • Bembridge, G.P.1    Rodriguez, N.2    Beato, G.R.3    Nicolson, C.4    Melero, J.A.5    Taylor, G.6
  • 93
    • 3042764814 scopus 로고    scopus 로고
    • Advances in respiratory syncytialvirus vaccine development
    • Kneyber MCJ, Kimpen JLL. Advances in respiratory syncytialvirus vaccine development. Cur Opin Invest Drugs 2004; 5: 163-70.
    • (2004) Cur Opin Invest Drugs , vol.5 , pp. 163-170
    • Kneyber, M.C.J.1    Kimpen, J.L.L.2
  • 94
    • 0034624098 scopus 로고    scopus 로고
    • Respiratory syncytial virus infection of gene gunvaccinated mice induces Th2 driven pulmonary eosinophilia even inthe absence of sensitisation to the fusion (F) or attachment (G)protein
    • Bembridge GP, Rodriguez N, Beato GR, Nicolson C, Melero JA,Taylor G. Respiratory syncytial virus infection of gene gunvaccinated mice induces Th2 driven pulmonary eosinophilia even inthe absence of sensitisation to the fusion (F) or attachment (G)protein. Vaccine 2000; 19: 1038-46.
    • (2000) Vaccine , vol.19 , pp. 1038-1046
    • Bembridge, G.P.1    Rodriguez, N.2    Beato, G.R.3    Nicolson, C.4    Melero, J.A.5    Taylor, G.6
  • 95
    • 5444257335 scopus 로고    scopus 로고
    • Gene gun DNA vaccination aggravates respiratory syncytial virusinduced pneumonitis
    • Bartholdy C, Olszewska W, Stryhn A, Thomsen AR, Openshaw PJ.Gene gun DNA vaccination aggravates respiratory syncytial virusinduced pneumonitis. J Gen Virol 2004; 85: 3017-26.
    • (2004) J Gen Virol , vol.85 , pp. 3017-3026
    • Bartholdy, C.1    Olszewska, W.2    Stryhn, A.3    Thomsen, A.R.4    Openshaw, P.J.5
  • 96
    • 0037471402 scopus 로고    scopus 로고
    • Nasal delivery of chitosan-DNA plasmid expressing epitopes ofrespiratory syncytial virus (RSV) induces protective CTL responsesin BALB/c mice
    • Iqbal M, Lin W, Jabbal-Gill I, Davis SS, Steward MW, Illum L.Nasal delivery of chitosan-DNA plasmid expressing epitopes ofrespiratory syncytial virus (RSV) induces protective CTL responsesin BALB/c mice. Vaccine 2003; 21:1478-85.
    • (2003) Vaccine , vol.21 , pp. 1478-1485
    • Iqbal, M.1    Lin, W.2    Jabbal-Gill, I.3    Davis, S.S.4    Steward, M.W.5    Illum, L.6
  • 98
    • 34548490545 scopus 로고    scopus 로고
    • Oralrespiratory syncytial virus (RSV) DNA vaccine expressing RSV Fprotein delivered by attenuated Salmonella typhimurium
    • Xie C, He JS, Zhang M, Xue SL, Wu Q, Ding XT, et al. Oralrespiratory syncytial virus (RSV) DNA vaccine expressing RSV Fprotein delivered by attenuated Salmonella typhimurium. HumGene Ther 2007; 18: 746-52.
    • (2007) HumGene Ther , vol.18 , pp. 746-752
    • Xie, C.1    He, J.S.2    Zhang, M.3    Xue, S.L.4    Wu, Q.5    Ding, X.T.6
  • 99
    • 34648840508 scopus 로고    scopus 로고
    • Immunogenicity andefficacy of codon optimized DNA vaccines encoding the F-proteinof respiratory syncytial virus
    • Ternette N, Tippler B, Uberla K, Grunwald T. Immunogenicity andefficacy of codon optimized DNA vaccines encoding the F-proteinof respiratory syncytial virus. Vaccine 2007; 25: 7271-9.
    • (2007) Vaccine , vol.25 , pp. 7271-7279
    • Ternette, N.1    Tippler, B.2    Uberla, K.3    Grunwald, T.4
  • 100
    • 38349066207 scopus 로고    scopus 로고
    • Polylactide-co-glycolide (PLG) microparticlesmodify the immune response to DNA vaccination
    • Helson R, Olszewska W, Singh M, Megede JZ, Melero JA,O'Hagan D, et al. Polylactide-co-glycolide (PLG) microparticlesmodify the immune response to DNA vaccination. Vaccine 2008;26: 753-61.
    • (2008) Vaccine , vol.26 , pp. 753-761
    • Helson, R.1    Olszewska, W.2    Singh, M.3    Megede, J.Z.4    Melero, J.A.5    O'Hagan, D.6
  • 101
    • 58149242781 scopus 로고    scopus 로고
    • Enhancement of mucosal and cellularimmune response in mice by vaccination with respiratory syncytialvirus DNA encapsulated with transfersome
    • Xu J, Ding Y, Yang Y. Enhancement of mucosal and cellularimmune response in mice by vaccination with respiratory syncytialvirus DNA encapsulated with transfersome. Viral Immunol 2008;21: 483-9.
    • (2008) Viral Immunol , vol.21 , pp. 483-489
    • Xu, J.1    Ding, Y.2    Yang, Y.3
  • 102
    • 39749187575 scopus 로고    scopus 로고
    • Single intranasal immunizationwith recombinant adenovirus-based vaccine induces protectiveimmunity against respiratory syncytial virus infection
    • Yu JR, Kim S, Lee JB, Chang J. Single intranasal immunizationwith recombinant adenovirus-based vaccine induces protectiveimmunity against respiratory syncytial virus infection. J Virol 2008;82: 2350-7.
    • (2008) J Virol , vol.82 , pp. 2350-2357
    • Yu, J.R.1    Kim, S.2    Lee, J.B.3    Chang, J.4
  • 103
    • 62949177862 scopus 로고    scopus 로고
    • Intranasalimmunization with a replication-deficient adenoviral vectorexpressing the fusion glycoprotein of respiratory syncytial viruselicits protective immunity in BALB/c mice
    • Fu Y, He J, Zheng X, Wu Q, Zhang M, Wang X, et al. Intranasalimmunization with a replication-deficient adenoviral vectorexpressing the fusion glycoprotein of respiratory syncytial viruselicits protective immunity in BALB/c mice. Biochem Biophys ResCommun 2009; 381: 528-32.
    • (2009) Biochem Biophys ResCommun , vol.381 , pp. 528-532
    • Fu, Y.1    He, J.2    Zheng, X.3    Wu, Q.4    Zhang, M.5    Wang, X.6
  • 104
    • 68549132243 scopus 로고    scopus 로고
    • Immunogenic properties of RSV-B1 fusion (F) protein gene-encoding recombinant adenoviruses
    • Shao HY, Yu SL, Sia C, Chen Y, Chitra E, Chen IH, et al.Immunogenic properties of RSV-B1 fusion (F) protein gene-encoding recombinant adenoviruses. Vaccine 2009; 27: 5460-71.
    • (2009) Vaccine , vol.27 , pp. 5460-5471
    • Shao, H.Y.1    Yu, S.L.2    Sia, C.3    Chen, Y.4    Chitra, E.5    Chen, I.H.6
  • 105
    • 1242338194 scopus 로고    scopus 로고
    • Vaccination of infant macaques with arecombinant modified vaccinia virus Ankara expressing therespiratory syncytial virus F and G genes does not predispose forimmunopathology
    • de Waal L, Wyatt LS, Yüksel S, van Amerongen G, Moss B,Niesters HG, et al. Vaccination of infant macaques with arecombinant modified vaccinia virus Ankara expressing therespiratory syncytial virus F and G genes does not predispose forimmunopathology. Vaccine 2004; 22: 923-6.
    • (2004) Vaccine , vol.22 , pp. 923-926
    • de Waal, L.1    Wyatt, L.S.2    Yüksel, S.3    van Amerongen, G.4    Moss, B.5    Niesters, H.G.6
  • 106
    • 12844268178 scopus 로고    scopus 로고
    • The Immunomodulating Properties of Human Respiratorysyncytial Virus and Immunostimulating Complexes ContainingQuillaja Saponin Components QH-A, QH-C and ISCOPREP 703
    • Hu KF, Regner M, Siegrist CA, Lambert P, Chen M, BengtssonKL, et al. The immunomodulating properties of human respiratorysyncytial virus and immunostimulating complexes containingQuillaja saponin components QH-A, QH-C and ISCOPREP 703.FEMS Immunol Med Microbiol 2005; 43: 269-76.
    • (2005) FEMS Immunol Med Microbiol , vol.43 , pp. 269-276
    • Hu, K.F.1    Regner, M.2    Siegrist, C.A.3    Lambert, P.4    Chen, M.5    Bengtsson, K.L.6
  • 107
    • 0030887353 scopus 로고    scopus 로고
    • Adjuvants influence the quantitative and qualitative immuneresponse in BALB/c mice immunized with respiratory syncytialvirus FG subunit vaccine
    • Neuzil KM, Johnson JE, Tang YW, Prieels JP, Slaoui M, Gar N,et al. Adjuvants influence the quantitative and qualitative immuneresponse in BALB/c mice immunized with respiratory syncytialvirus FG subunit vaccine. Vaccine 1997; 15: 525-32.
    • (1997) Vaccine , vol.15 , pp. 525-532
    • Neuzil, K.M.1    Johnson, J.E.2    Tang, Y.W.3    Prieels, J.P.4    Slaoui, M.5    Gar, N.6
  • 108
    • 0034507382 scopus 로고    scopus 로고
    • QS-21 synergizes withrecombinant interleukin 12 to create a potent adjuvant formulationfor the fusion protein of respiratory syncytial virus
    • Hancock GE, Heers KM, Smith JD. QS-21 synergizes withrecombinant interleukin 12 to create a potent adjuvant formulationfor the fusion protein of respiratory syncytial virus. Viral Immunol2000; 13: 503-9.
    • (2000) Viral Immunol , vol.13 , pp. 503-509
    • Hancock, G.E.1    Heers, K.M.2    Smith, J.D.3
  • 109
    • 0034081441 scopus 로고    scopus 로고
    • CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratorysyncytial virus in the BALB/c mouse
    • Tripp RA, Jones L, Anderson LJ, Brown MP. CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratorysyncytial virus in the BALB/c mouse. J Immunol 2000; 164: 5913-21.
    • (2000) J Immunol , vol.164 , pp. 5913-5921
    • Tripp, R.A.1    Jones, L.2    Anderson, L.J.3    Brown, M.P.4
  • 110
    • 0035860575 scopus 로고    scopus 로고
    • CpG containing oligodeoxynucleotides are potentadjuvants for parenteral vaccination with the fusion (F) protein ofrespiratory syncytial virus (RSV)
    • Hancock GE, Heers KM, Smith JD, Scheuer CA, Ibraghimov AR,Pryharski KS. CpG containing oligodeoxynucleotides are potentadjuvants for parenteral vaccination with the fusion (F) protein ofrespiratory syncytial virus (RSV). Vaccine 2001; 19: 4874-82.
    • (2001) Vaccine , vol.19 , pp. 4874-4882
    • Hancock, G.E.1    Heers, K.M.2    Smith, J.D.3    Scheuer, C.A.4    Ibraghimov, A.R.5    Pryharski, K.S.6
  • 111
    • 0346817398 scopus 로고    scopus 로고
    • Adjuvants recognized by toll-like receptors inhibit the induction ofpolarized type 2 T cell responses by natural attachment (G) proteinof respiratory syncytial virus
    • Hancock GE, Heers KM, Pryharski KS, Smith JD, Tiberio L.Adjuvants recognized by toll-like receptors inhibit the induction ofpolarized type 2 T cell responses by natural attachment (G) proteinof respiratory syncytial virus. Vaccine 2003; 21: 4348-58.
    • (2003) Vaccine , vol.21 , pp. 4348-4358
    • Hancock, G.E.1    Heers, K.M.2    Pryharski, K.S.3    Smith, J.D.4    Tiberio, L.5
  • 112
    • 67349253124 scopus 로고    scopus 로고
    • TLR9agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapyduring primary RSV infection increases disease severity
    • Johnson TR, Rao S, Seder RA, Chen M, Graham BS. TLR9agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapyduring primary RSV infection increases disease severity. Vaccine2009; 27: 3045-52.
    • (2009) Vaccine , vol.27 , pp. 3045-3052
    • Johnson, T.R.1    Rao, S.2    Seder, R.A.3    Chen, M.4    Graham, B.S.5
  • 113
    • 0031902954 scopus 로고    scopus 로고
    • The immunostimulating complex (ISCOM) is anefficient mucosal delivery system for respiratory syncytial virus(RSV) envelope antigens inducing high local and systemic antibodyresponses
    • Hu KF, Elvander M, Merza M, Akerblom L, Brandenburg A,Morein B. The immunostimulating complex (ISCOM) is anefficient mucosal delivery system for respiratory syncytial virus(RSV) envelope antigens inducing high local and systemic antibodyresponses. Clin Exp Immunol 1998; 113: 235-43.
    • (1998) Clin Exp Immunol , vol.113 , pp. 235-243
    • Hu, K.F.1    Elvander, M.2    Merza, M.3    Akerblom, L.4    Brandenburg, A.5    Morein, B.6
  • 114
    • 0035940308 scopus 로고    scopus 로고
    • Immunostimulatingcomplexes (ISCOMs) for nasal vaccination
    • Hu KF, Lovgren-Bengtsson K, Morein B. Immunostimulatingcomplexes (ISCOMs) for nasal vaccination. Adv Drug Deliv Rev2001; 51: 149-59.
    • (2001) Adv Drug Deliv Rev , vol.51 , pp. 149-159
    • Hu, K.F.1    Lovgren-Bengtsson, K.2    Morein, B.3
  • 116
    • 77954036588 scopus 로고    scopus 로고
    • Combination vaccineagainst Streptococcus pneumoniae and respiratory syncytial virus(RSV)
    • Deschamps, M., Laferriere, C., Joseph, A. Combination vaccineagainst Streptococcus pneumoniae and respiratory syncytial virus(RSV). EP1927366A1 (2008).
    • (2008) EP1927366A1
    • Deschamps, M.1    Laferriere, C.2    Joseph, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.